Research Type: Assessment

2017 Review: Relapsing-Remitting MS and Primary Progressive MS Interventions of Interest: Injectable Agents Daclizumab (Zinbryta®, Biogen/AbbVie) Glatiramer acetate (Copaxone®, Teva) Glatiramer acetate (Glatopa®, Sandoz (Novartis)) Interferon beta-1a (Avonex®, Biogen) Interferon beta-1b (Betaseron®, Bayer) Interferon beta-1b (Extavia®, Novartis) Interferon beta-1a (Rebif®, EMD Serono) Peginterferon beta-1a (Plegridy®, Biogen) Oral Agents Dimethyl fumarate (Tecfidera®, Biogen) Fingolimod (Gilenya®, Novartis) […]

2019 Review: Secondary Progressive MS Intervention of Interest: Siponimod (MAYZENT®, Novartis) Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system.Relapsing-remitting MS (RRMS) is the most common disease course and is characterizedby periods of worsening neurologic symptoms (“relapses”) followed by partial or completerecovery. Incomplete recovery from relapses may contribute to worsening neurologic function […]

Intervention of interest: Cervical spinal fusion We completed a Technology Assessment of cervical spinal fusion for degenerative disc disease in advance of the public meeting of the Washington State Health Technology Assessment Program’s Clinical Committee. Date of review: March 2013 For questions or additional information, please contact info@icer.org Final Documents Below you will find the […]

Intervention of Interest: Obeticholic Acid (OCALIVA®, Intercept Pharmaceuticals, Inc.) Obeticholic acid (OCA) is a novel bile acid analogue that has shown positive effects on biochemical markers of liver function in phase II trials and was approved by the FDA for treatment of primary biliary cholangitis (PBC) after failure of ursodeoxycholic Acid (UDCA). Primary biliary cholangitis (PBC), […]

ICER planned to assess the comparative clinical effectiveness and value of obeticholic acid (Intercept) for the treatment of non-alcoholic steatohepatitis (NASH). For questions, please contact info@icer.org. Update as of July 1, 2020: ICER will not hold the August 2020 Midwest CEPAC public meeting to discuss the comparative clinical effectiveness and value assessment of obeticholic acid […]

Interventions of Interest: Tyrosine kinase inhibitors: Afatinib (Gilotrif®, Boehringer Ingelheim Pharmaceuticals, Inc.) Erlotinib (Tarceva®, Genentech, Inc. and Astellas Pharma US, Inc.) Gefitinib (Iressa®, AstraZeneca) Immunotherapies targeting the programmed death 1 (PD-1) receptor or its ligand (PD-L1): Atezolizumab (Tecentriq®, Genentech, Inc., Roche Group) Nivolumab (Opdivo®, Bristol-Meyers Squibb Co.) Pembrolizumab (Keytruda®, Merck & Co.) Lung cancer is […]

Interventions of interest: Home sleep testing Polysomnography Continuous positive airway pressure (CPAP) Mandibular advancement devices (MADs) Surgical procedures Weight loss interventions Obstructive sleep apnea (OSA) is a chronic disorder, characterized by repetitive stops and starts in breathing during a night of sleep. As muscles in the throat relax, partial (hypopnea) or complete (apnea) blockage of […]

Interventions of Interest: Buprenorphine (Subutex®, Reckitt Benckiser Pharmaceuticals Inc. Buprenorphine and naloxone (Suboxone®, Indivior Inc.) Dose-tapering strategies for methadone or Suboxone, with or without naltrexone (Revia®, Duramed Pharmaceuticals, Inc. Naltrexone (Vivitrol®, Alkermes, Inc.) Use of naltrexone alone without prior stabilization on methadone or buprenorphine Drug-free opioid withdrawal management A 2014 review assessed MAT with methadone […]

Interventions of interest: Monthly buprenorphine injection (Sublocade™, Indivior) Buprenorphine implant (Probuphine®, Braeburn/Titan) Buprenorphine extended release injection (Sublocade®, Braeburn) These therapies were compared to MAT with methadone, buprenorphine/naloxone sublingual film (Suboxone®, Indivior), and injectable naltrexone (Vivitrol®, Alkermes). Opioid use disorder has reached a critical level in the United States, driven by over-prescription and diversion of opioid […]

ICER assessed the comparative clinical effectiveness and economic value of supervised injection facilities (SIFs). ICER has reviewed other related topics, such as abuse-deterrent opioid formulations, medication-assisted treatment for opioid use disorder, and non-drug interventions for lower back pain. This review reinforced ICER’s commitment to provide an independent evaluation of the evidence around interventions that target […]